نتایج جستجو برای: enoxaparin

تعداد نتایج: 1833  

Objective: Heparin and enoxaparin possess anti-inflammatory properties. We compared the effects of these drugs on inflammatory biomarkers in patients with ST-segment Elevated Myocardial Infarction (STEMI). Method: Thirty four patients with STEMI randomly separated in two groups and received standard doses of heparin and enoxaparin. The serum concentration of Serum Amyloid A (SAA), C-Reactive Pr...

Journal: :Critical care medicine 2001
A F Shorr A S Ramage

OBJECTIVE To determine the cost-effectiveness of enoxaparin compared with low-dose-heparin (LDH) for thromboprophylaxis after major trauma and to assess the economic significance of major bleeding as a complication of the use of low-molecular-weight heparin (LMWH). DESIGN Decision model analysis of the cost and efficacy of enoxaparin at preventing venous thromboembolism (VTE) and the risk and...

Journal: :Lancet 2007
David G Sherman Gregory W Albers Christopher Bladin Cesare Fieschi Alberto A Gabbai Carlos S Kase William O'Riordan Graham F Pineo

BACKGROUND Venous thromboembolism prophylaxis with low molecular weight heparin or unfractionated heparin is recommended in acute ischaemic stroke, but which regimen provides optimum treatment is uncertain. We aimed to compare the efficacy and safety of enoxaparin with that of unfractionated heparin for patients with stroke. METHODS 1762 patients with acute ischaemic stroke who were unable to...

Journal: :Clinical journal of the American Society of Nephrology : CJASN 2007
Urs Benck Sarah Haeckel John H Clorius Fokko J van der Woude

Angiotensin-converting enzyme inhibitors and angiotensin II (AngII) type 1 receptor blockers lower proteinuria and preserve renal function in diabetic nephropathy (DN). The antiproteinuric effects are greater than their blood pressure reduction, involving the sieving properties of the glomerular filter. In DN, glomerular staining for heparan sulfate proteoglycans is decreased. AngII inhibits he...

Journal: :Journal of thrombosis and haemostasis : JTH 2010
J A M Anderson J Hirsh S Yusuf M Johnston R Afzal S R Mehta K A A Fox A Budaj J W Eikelboom

BACKGROUND In the OASIS-5 trial, fondaparinux reduced major bleeding with similar short-term efficacy as enoxaparin but lowered death and stroke during long-term follow-up. The mechanism of lower bleeding and improved efficacy with fondaparinux is uncertain. METHODS AND RESULTS We compared the anti-Xa concentration (reflecting drug levels), Xa clot time (reflecting anticoagulant effect) and e...

Journal: :Technology and health care : official journal of the European Society for Engineering and Medicine 2014
Philipp Mommsen Matthias Doering Ehrenfried R O Hrs Claus Egidy Thorsten Gehrke Christian Krettek Daniel Kendoff

BACKGROUND Low-molecular-weight heparins (LMWH), e.g. enoxaparin, represent the standard thromboprophylactic agents in Europe after total hip replacement. The oral direct thrombin inhibitor dabigatran etexilate provides comparable effectiveness and safety. The present study aimed to evaluate the influence of dabigatran etexilate on perioperative blood loss and wound secretion in total hip arthr...

Journal: :Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2003
Benjamin Guillet Nicolas Simon Jérôme José Sampol Anne-Marie Lorec-Penet Henri Portugal Yvon Berland Bertrand Dussol Philippe Brunet

BACKGROUND The interest of low molecular weight heparins (LMWH) regarding bleeding risk is controversial in renal failure patients. In haemodialysis patients, there are very few data on the pharmacokinetics of LMWH after the end of the session. The aim of the study was to evaluate the duration of anticoagulation after bolus administration of the LMWH enoxaparin at the start of haemodialysis. ...

2016
Isa An Mehmet Harman Ibrahim Ibiloglu

Bullous hemorrhagic dermatosis induced by enoxaparin is a rare, self-limiting, cutaneous adverse reaction causing no complications. In this report, we present a case where bullous hemorrhagic dermatosis developed at a location distant from the site of injection after using enoxaparin for 5 days for pulmonary venous thrombosis.

Journal: :American heart journal 2000
B J O'Brien A Willan G Blackhouse R Goeree M Cohen S Goodman

BACKGROUND One-year follow-up data from the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) trial show that use of low-molecular-weight heparin (enoxaparin) compared with unfractionated heparin in patients hospitalized with unstable angina or non-Q-wave myocardial infarction is associated with a 10% reduction in the cumulative 1-year risk of death, myocard...

Journal: :International journal of medical and pharmaceutical case reports 2023

An 87-year-old female with a history of paraplegia/neurogenic bladder, chronic left leg wound infection, and recurrent UTI, was admitted primary problem frequent falls found to have COVID-19 infection. Upon admission, the patient given enoxaparin for DVT prophylaxis hypercoagulability due COVID-19. After 3 days initiation enoxaparin, experienced hyponatremia trending upward levels potassium. It...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید